https://www.selleckchem.com/pr....oducts/butyzamide.ht
Increases in MAPK1 expression eliminated miR‑101‑3p inhibition of IL‑10 and IFN‑γ. MAPK1 activated the NF‑κB pathway in SLE PBMCs and this activation was inhibited when miR‑101‑3p was overexpressed. In addition, treatment with BAY11‑7085 (NF‑κB activator) was demonstrated to reverse the inhibitory effects of miR‑101‑3p expression on both IL‑10 and IFN‑γ in SLE PBMCs. BAY11‑7082 also markedly reduced MAPK1‑induced increases in IL‑10 and IFN‑γ in SLE PBMCs. miR‑101‑3p overexpression attenuated the inflammatory response in SLE PBMCs by
Like
Comment
Share
